Clinical Research Directory

Inclusion Criteria: 1. Age ≥ 18 years 2. Histopathologically confirmed solid tumors in one of the following cohorts: 1. Cohort 1 (n=15): Histologically confirmed prostate cancer, with castration resistant disease per Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria. 2. Cohort 2 (n=15): Histologically confirmed high grade neuroendocrine tumor, with a Ki-67 over 20. 3. Cohort 3 (n=15): Agnostic to tumor type. 3. Metastatic disease present on conventional imaging defined as having Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 measurable disease or multiple bone metastases. 4. Ability to understand a written informed consent document, and the willingness to sign it. Exclusion Criteria: 1. Unlikely to comply with protocol procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation. 2. Has known hypersensitivity to Chinese hamster ovary cell products. 3. Has a history of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins. 4. Known pregnancy.